Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Michael Mannion"'
Autor:
Michael Mannion
Publikováno v:
Alternative and Complementary Therapies. 3:194-199
Autor:
James McElnay, Jon S Brazier, Michael G. Scott, Peter Flanagan, M. P. Kearney, Brian Smyth, Fidelma A. Magee, Collette Edwards, Avril Craig, Stéphan Juergen Harbarth, Mamoon A. Aldeyab, Brendan Gilmore, Chris Funston, Michael J Devine, Shaunagh Small, Elizabeth Davies, Geraldine Conlon, Nathalie Vernaz, Feras Darwish El-Hajji, Michael Mannion
Publikováno v:
Infection Control and Hospital Epidemiology, Vol. 32, No 3 (2011) pp. 210-9
Objective.To report a large outbreak ofClostridium difficileinfection (CDI; ribotype 027) between June 2007 and August 2008, describe infection control measures, and evaluate the impact of restricting the use of fluoroquinolones in controlling the ou
Autor:
Michael Mannion, James Wang, Jeffrey M. Besterman, Stephane Raeppel, Normand Beaulieu, Isabelle Dupont, Ljubomir Isakovic, Arkadii Vaisburg, Carole Beaulieu, Hannah Nguyen, Oscar Mario Saavedra, Robert Deziel, Christiane R. Maroun, A. Robert MacLeod, Stephen William Claridge, Frédéric Gaudette
Publikováno v:
Bioorganicmedicinal chemistry letters. 20(9)
A novel series of N-(3-fluoro-4-(2-substituted-thieno[3,2-b]pyridin-7-yloxy)phenyl)-1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxamides targeting RON receptor tyrosine kinase was designed and synthesized. SAR study of the series allowed us to ide
Autor:
Jeffrey M. Besterman, Naomy Bernstein, Hannah Nguyen, Franck Raeppel, Lijie Zhan, Stephane Raeppel, James Wang, A. Robert MacLeod, Marie-Claude Granger, Ljubomir Isakovic, Stephen William Claridge, Normand Beaulieu, Carole Beaulieu, Oscar Mario Saavedra, Frédéric Gaudette, Arkadii Vaisburg, Isabelle Dupont, Michael Mannion, Nancy Z. Zhou, Robert Deziel
Publikováno v:
Bioorganicmedicinal chemistry letters. 19(24)
A family of thieno[3,2-b]pyridine based small molecule inhibitors of c-Met and VEGFR2 were designed based on lead structure 2. These compounds were shown to have IC(50) values in the low nanomolar range in vitro and were efficacious in human tumor xe
Autor:
Carole Beaulieu, Marja Dubay, Jeffrey M. Besterman, Stephane Raeppel, Jubrail Rahil, Nancy Z. Zhou, Ian Chute, Arkadii Vaisburg, Lijie Zhan, Isabelle Dupont, Hannah Nguyen, Ljubomir Isakovic, James Wang, Robert Deziel, Stephen William Claridge, Frédéric Gaudette, A. Robert MacLeod, Normand Beaulieu, Hélène Ste-Croix, Marie-France Robert, Sylvain Lefebvre, Oscar Mario Saavedra, Michael Mannion, Franck Raeppel
Publikováno v:
Bioorganicmedicinal chemistry letters. 19(23)
A series of N-(4-(6,7-disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides targeting c-Met and VEGFR2 tyrosine kinases was designed and synthesized. The compounds were potent against these two enzymes with IC(50)
Autor:
Stephen William Claridge, Arkadii Vaisburg, Claire Bonfils, Jeffrey M. Besterman, Stephane Raeppel, James Wang, Marielle Fournel, Helene Sainte-Croix, Lubo Isakovic, Normand Beaulieu, Oscar Mario Saavedra, Franck Raeppel, Michael Mannion, Christiane R. Maroun
Publikováno v:
Cancer Research. 73:930-930
Despite breakthroughs in the clinical development of tyrosine kinase inhibitors, challenges remain in overcoming resistance to these molecular targeted therapies. Advances in our understanding of mechanisms of resistance to targeted agents will impro
Autor:
Marielle Fournel, Marja Dubay, Christian Lemoyne, Stephen William Claridge, Arkadii Vaisburg, Michael Mannion, Robert E. Martell, Lubo Isakovic, Oscar Mario Saavedra, Franck Raeppel, Claire Bonfils, Normand Beaulieu, Hélène Ste-Croix, Carole Beaulieu, Stephane Raeppel, Jeffrey M. Besterman, James Wang, Isabelle Dupont, Christiane R. Maroun
Publikováno v:
Cancer Research. 70:3612-3612
MGCD265 is an oral multitargeted receptor tyrosine kinase inhibitor in Phase II clinical development. MGCD265 targets the Met receptor tyrosine kinase and blocks Met activities which contribute to cancer development and progression such as cell proli
Autor:
Isabelle Dupont, Claire Bonfils, Christiane R. Maroun, Arkadii Vaisburg, Lubo Isakovic, Stephen William Claridge, Jeffrey M. Besterman, Marja Dubay, Stephane Raeppel, Hélène Ste-Croix, Normand Beaulieu, Franck Raeppel, Oscar Mario Saavedra, Michael Mannion
Publikováno v:
Cancer Research. 70:3609-3609
MGCD265 is a multitargeted receptor tyrosine kinase inhibitor in Phase II clinical development, which inhibits the activation of regulators of cancer development and progression by targeting Met, the three members of the VEGFR family, Tie-2 and Ron.